featured
-
The Great Care Conundrum: What “Good” Care Looks Like in Huntington’s Disease
⏱️8 min read | What does “good care” look like in Huntington’s Disease? A new Dutch study asked familial and professional caregivers, and uncovered how differently it’s experienced in practice.
By Eva Woods -
A Second Path: uniQure Plans Regulatory Filing for AMT-130 in the UK
⏱️ 6 min read | While the US regulatory path for AMT-130 remains complicated, uniQure announced plans to seek approval for its HD gene therapy in the UK. Here’s what that means, and what might be to come.
-
Two Years In: New Long-Term Extension Data from PIVOT-HD for Votoplam
⏱️10 min read | PTC Therapeutics shared 2-year data for votoplam, a daily HTT-lowering pill. Stage 2 participants showed up to 52% slowing of disease progression. Here’s what the data show, what’s still missing, and the roll out of the Phase 3 trial.
-
April 2026: This Month in Huntington’s Disease Research
⏱️ 8 min read | April 2026 showed us a toxic HTT fragment is center stage in mouse research, CRISPR is showing promise in mouse studies, AI and wearables move closer to the clinic, and 2 studies shine a light on the weight carried by HD caregivers.
-
The Number on the Scale: What the TFC Score Measures, and Why It Matters Right Now
⏱️ 10 min read | The Total Functional Capacity score has been used in Huntington’s disease research for decades. Here’s what it measures, what it misses, & why it’s at the center of an anticipated clinical trial.
-
Dancing With a Stranger: Understanding Apathy in Huntington’s Disease Through Caregivers
⏱️5 min read | Apathy in HD isn’t just “not caring.” It can affect relationships, routines, and emotional connection. A small study of caregivers reveals the heavy toll of apathy and the value of safe spaces to share experiences.
-
Fund the Buzz: The $8,000 Reason HDBuzz Can Tell You the Truth
⏱️ 6 min read | HDBuzz is launching Fund the Buzz, our spring fundraising campaign! We’re independent, pharma funding-free, and run by scientists who know HD. Help us keep the lights on (and stay lawsuit-free).
-
Cutting to the chase with CRISPR
⏱️ 6 min read | A new study uses “self-switching” genetic scissors to target the root cause of Huntington’s disease in mice – even after symptoms begin.
-
Artificial Intelligence enters the HD space as a diagnostic tool
⏱️9 min read | From predicting symptom onset to tracking movement changes via smartwatch, artificial intelligence tools are being used in research. Here’s where we are, and why Huntington’s disease is a strong candidate for these approaches.
-
Blocking a toxic fragment: new mouse study highlights the importance of HTT1a in Huntington’s disease
⏱️ 9 min read |New research in a HD mouse model points to a key culprit: a small fragment called HTT1a. Lowering HTT1a levels successfully delayed disease signs in mice that model HD, perhaps shaping the next generation of HTT-lowering therapies.